Opendata, web and dolomites

BIOXPLOR SIGNED

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BIOXPLOR project word cloud

Explore the words cloud of the BIOXPLOR project. It provides you a very rough idea of what is the project "BIOXPLOR" about.

id    solution    pharma    stratification    bioxplor    merck    eur500k    secondary    drug    multiyear    negotiating    biomarker    successfully    partnered    inflammation    programs    2m    recombinant    70    tlr    stage    deploying    25x    revenue    pilots    biotech    customers    2021    genomes    skydeck    100k    abcam    ai    novartis    forum    tested    leads    clinical    uc    oncology    submissions    march    bayer    reduces    expansion    15    score    patient    proteins    environments    biosimilars    building    last    excellence    cognitive    rare    company    inflammatory    institutes    software    diseases    indication    discovery    shown    edemedx    pipeline    5x    academic    data    primary    tests    antibodies    accelerates    09    berkeley    seal    time    contracts    gained    orders    savings    acceleration    platform    acquiring    repositioning    2018    super    submission    companies    requested    projected    responder    2019    13    eur750k    progress    november    immunoassays    revenues    trials    space   

Project "BIOXPLOR" data sheet

The following table provides information about the project.

Coordinator
BIOXPLOR LIMITED 

Organization address
address: 9C THE BOTTLEWORKS
city: Dublin
postcode: Dublin 4
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://bioxplor.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOXPLOR LIMITED IE (Dublin) coordinator 50˙000.00

Map

 Project objective

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction in time and 70% cost savings in pilots so far. (TLR stage 6 &7 tests in 5x Biotech and Pharma companies). BioXplor has achieved the Seal of Excellence for our Phase I application in March 2019 (score 13.5) and November 2018 (score 13.09) submissions. Last year, we have been completed acceleration programs at UC Berkeley’s SkyDeck and at Merck, and since then significant progress in building the platform to TLR stage 7 and acquiring new customers and revenue. The platform has been successfully used in tests with 5x Pharma and biotech companies (Merck, Bayer, Novartis, Abcam, EdemedX), and we have 5 new leads, for our platform for Discovery applications (antibodies, recombinant proteins, biomarker discovery, immunoassays, drug target ID) and Clinical applications (indication expansion, super-responder ID for drug-repositioning, and patient stratification for Biosimilars, all in inflammation projects with Biotech and Pharma). The current submission is aimed towards bringing BioXplor’s Platform to TLR stage 8, and deploying the our fully tested solution in operational environments at Pharma, Biotech and Academic Research Institutes, for which we are already negotiating pre-orders including 3 year multiyear contracts and 5-10 year partnerships. We have since partnered UC Berkeley, gained access to clinical trials patient data from a major pharma, become a discovery forum member with the 100K Genomes Project, and been selected as a consortium partner for an EU project in the oncology space. We have built a pipeline of EUR750k, with 2019 revenues projected at EUR500k and project revenues of $2M by 2021. We have been requested to deliver the solution to manage 15-20 clinical trials (secondary use of data) for a Top 2 Pharma company

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOXPLOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOXPLOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More